Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2

  1. Laura N Jeffreys
  2. Shaun H Pennington
  3. Jack Duggan
  4. Claire H Caygill
  5. Rose C Lopeman
  6. Alastair F Breen
  7. Jessica B Jinks
  8. Alison Ardrey
  9. Samantha Donnellan
  10. Edward I Patterson
  11. Grant L Hughes
  12. David W Hong
  13. Paul M O’Neill
  14. Ghaith Aljayyoussi
  15. Andrew Owen
  16. Stephen A Ward
  17. Giancarlo A Biagini

Reviewed by

Read the full article

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

A key element for the prevention and management of COVID-19 is the development of effective therapeutics. Drug combination strategies of repurposed drugs offer several advantages over monotherapies, including the potential to achieve greater efficacy, the potential to increase the therapeutic index of drugs and the potential to reduce the emergence of drug resistance. Here, we report on the in vitro synergistic interaction between two FDA approved drugs, remdesivir and ivermectin resulting in enhanced antiviral activity against SARS-CoV-2. These findings warrant further investigations into the clinical potential of this combination, together with studies to define the underlying mechanism.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2020.12.23.424232: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    VERO E6 cell culture and plate preparation: VERO E6 cells were maintained in complete EMEM (EMEM supplemented with 10% heat-inactivated FBS [Gibco; 10500-064] and 1% penicillin/streptomycin [Gibco; 15140-122]) at 37 °C with 5 % CO2.
    VERO E6
    suggested: None
    Software and Algorithms
    SentencesResources
    VERO E6 cell culture and plate preparation: VERO E6 cells were maintained in complete EMEM (EMEM supplemented with 10% heat-inactivated FBS [Gibco; 10500-064] and 1% penicillin/streptomycin [Gibco; 15140-122]) at 37 °C with 5 % CO2.
    Gibco
    suggested: None

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2020.12.23.424232 on bioRxiv